<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Mottas, Inès</dc:creator>
  <dc:creator>Bekdemir, Ahmet</dc:creator>
  <dc:creator>Cereghetti, Alessandra</dc:creator>
  <dc:creator>Spagnuolo, Lorenzo</dc:creator>
  <dc:creator>Yang, Yu-Sang Sabrina</dc:creator>
  <dc:creator>Müller, Marie</dc:creator>
  <dc:creator>J.Irvine, Darrell</dc:creator>
  <dc:creator>Stellaccic, Francesco</dc:creator>
  <dc:creator>Bourquin, Carole</dc:creator>
  <dc:date>2019-01-01</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Although immunotherapy shows great promise for the long-term control of cancer,  many tumors still fail to respond to treatment. To improve the outcome, the delivery of  immunostimulants to the lymph nodes draining the tumor, where the antitumor  immune response is initiated, is key. Efforts to use nanoparticles as carriers for cancer  immunotherapy have generally required targeting agents and chemical modification of  the drug, and have unfortunately resulted in low delivery and therapeutic efficiency.  Here, we report on the efficacy of gold nanoparticles with approximately 5 nm  hydrodynamic diameter coated with a mixture of 1-octanethiol and 11-  mercaptoundecanesulfonic acid for the delivery of an immunostimulatory TLR7 ligand  to tumor-draining lymph nodes. The drug was loaded without modification through  nonspecific adsorption into the ligand shell of the nanoparticles, taking advantage of  their amphiphilic nature. After loading, nanoparticles retained their stability in solution  without significant premature release of the drug, and the drug cargo was  immunologically active. Upon subcutaneous injection into tumor-bearing mice, the  drug-loaded particles were rapidly transported to the tumor-draining lymph nodes.  There, they induced a local immune activation and fostered a cytotoxic T-cell  response that was specific for the tumor. Importantly, the particle-delivered TLR7  ligand blocked the growth of large established tumors and significantly prolonged  survival compared to the free form of the drug. Thus, we demonstrate for the first time  that nanoparticle delivery of a TLR7 immunostimulant to the tumor-draining lymph  nodes enhances antitumor immunity and improves the outcome of cancer  immunotherapy.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/307624</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/307624/files/mot_and.pdf</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/307624/files/mot_and_sm.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.biomaterials.2018.10.031</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>Biomaterials. - 2019, vol. 190–191, p. 111–120</dc:source>
  <dc:subject>info:eu-repo/classification/udc/57</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">Amphiphilic nanoparticle delivery enhances the anticancer efficacy of a TLR7 ligand via local immune activation</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
